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Abstract  
Background: The role of community pharmacists continues to expand with immunizations, medication therapy management, and 
point-of-care testing (POCT). Current guidelines recommend that Human Immunodeficiency Virus (HIV) and Hepatitis C (HCV) testing 
become integrated into routine care. Current guidelines recommend all people aged 13-64 be tested for HIV at least once in their 
lifetime, with those at higher risk for HIV tested at least annually.1 Regarding HCV, current guidelines recommend a one-time HCV test 
in persons born from 1945 to 1965, as well as other individuals based on exposures, behaviors, and conditions or circumstances that 
increase HCV infection risk.2 Currently available HIV and HCV treatment regimens are safe and highly effective. With HCV, successful 
treatment can halt disease progression to cirrhosis, end-stage liver disease, and hepatocellular carcinoma.3 POCT in community 
pharmacy offers an ideal location due to its accessibility, convenience, and lower cost to patients who might not otherwise be tested. 
However, HIV and HCV screenings are not routinely conducted by community pharmacists due to many barriers. Though many barriers 
to HIV and HCV POCT have been identified at the patient, provider, and institutional level, little is known about pharmacist-perceived 
barriers. It is worth noting that the barrier of state legislation limiting POCT in pharmacies has been resolved – currently 49 states have 
some form of statute that allows for delegation of prescriptive authority between a prescriber and community pharmacist.4 Though 
this removed barrier means increased availability of POCT, as the studies above have demonstrated, the mere availability of POCT is 
not enough for its implementation. 
Objective: The main objective of this study is to identify pharmacist-perceived barriers and their level of confidence in performing 
community pharmacy-based POCT for HIV and HCV.  
Methods: A cross-sectional survey was sent to all pharmacists working in a regional grocery store chain to evaluate their opinions and 
attitudes toward the implementation of POCT for HIV and HCV. The electronic survey questions consisted of Likert scale, select-all-that-
apply, yes/no and no open-ended questions. 
Results: The perceived barriers to implementation of HIV and HCV POCT in a community setting identified by pharmacists include 
staffing, time to conduct test, patient out-of-pocket cost, and discussion of positive results. Pharmacists’ perceived level of confidence 
was greatest with providing basic education and incorporating HIV and HCV POCT into workflow; whereas discussion of a positive result 
was perceived as less confident.   
Conclusions: While this survey determined pharmacist support for the implementation of HIV and HCV POCT, additional studies are 
needed before effective implementation of HIV and HCV POCT in a community pharmacy chain.  
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Introduction 
Current U.S. guidelines recommend that HIV and HCV testing 
become integrated into routine care, and that novel 
approaches, such as point-of-care-testing (POCT), are needed 
to make testing more accessible, especially in patients who 
have never been tested.5 According to the Centers for Disease 
Control and Prevention (CDC), there were 39,782 newly 
diagnosed patients with Human Immunodeficiency Virus (HIV) 
in the U.S., an overall decrease of 5% from 2011 to 2015.6 While 
this decline is likely from targeted HIV prevention efforts, this 
progress has been uneven, with annual infections and 
diagnoses increasing among a few groups. For  example,   from  
 
___________________________________________________ 
Corresponding author: Elizabeth So, PharmD, MBA 
PGY-1 Pharmacy Resident, SUPERVALU/Cub Pharmacies 
3620 Texas Ave S, St Louis Park, MN 55426 
Phone: 952-933-3177; Fax: 952-933-4187 
Email: elizabethso1070@gmail.com  
2011 to 2015, HIV diagnoses increased 14% among Hispanic gay 
and bisexual men.6 Hepatitis C (HCV) is now recognized as the 
most common, chronic blood borne infection in the U.S.7 
According to the CDC, there were 2,436 people newly 
diagnosed with HCV, an overall increase of 49% from 2011 to 
2015.8 Risk factors for HIV include men who have sex with men 
(MSM), having sex with an HIV-positive partner, having more 
than one sex partner since last HIV test, using injectable drugs, 
sharing needles or works, exchanging sex for drugs or money, 
diagnosis of a sexually transmitted disease, hepatitis or 
tuberculosis, and having sex with someone whose sexual 
history is unknown.9 The CDC recommends HCV testing for all 
people in the U.S. born from 1945 to 1965, prior recipients of 
transfusions or organ transplants, and prior or current users of 
injectable drugs.10 
 
Community pharmacies are an ideal testing location because of 
their accessibility, convenience, and less stigmatization than 
traditional testing sites.11  With about 60,000 community 
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pharmacies in the U.S, many open nights, weekends, and 
holidays, and 89% of Americans living within five miles of a 
community pharmacy, the community pharmacist has long 
been recognized as the most accessible healthcare provider.4 In 
addition, POCT takes about 20 minutes to complete in one visit, 
as compared to two weeks when sending tests to established 
laboratories.12 However, many barriers have prevented 
implementation of POCT for HIV and HCV in a variety of 
settings. Though many barriers to HIV and HCV POCT have been 
identified at the patient, provider, and institutional level, little 
is known about pharmacist-perceived barriers. The main 
objective of this study is to identify pharmacist-perceived 
barriers and level of confidence in performing community 
pharmacy-based POCT for HIV and HCV.  
 
Methods 
Sample, Data Collection and Analysis 
This cross-sectional, online survey was utilized because of its 
timesaving opportunity, convenience, cost-efficiency, reach, 
anonymity, objectivity, and quick results.13 The survey included 
20 optional Likert scale, select-all-that-apply, and yes/no 
questions administered via SurveyMonkey®. These survey 
questions can be found in Appendix A. Surveys were emailed to 
all full-time, part-time, and relief pharmacists employed by a 
regional grocery store chain operating in the states of Illinois, 
Maryland, Minnesota, Missouri, North Carolina, and Virginia. 
Data collection occurred between December 2nd, 2017 and 
January 2nd, 2018, with a reminder to complete the survey 
emailed two weeks after the initial email. A descriptive analysis 
of statistics was performed using SurveyMonkey® in order to 
evaluate pharmacists’ opinions and attitudes toward the 482 of 
POCT for HIV and HCV. The study was determined to be exempt 
by the University of Minnesota Institutional Review Board as 
non-human subject research. 
  
Results  
482 pharmacists were sent an invitation to participate in the 
survey, with 224 located in Minnesota, 111 in Virginia, 60 in 
Missouri, 53 in Maryland, 20 in Illinois, and 2 in North Carolina. 
113 pharmacists accepted the invitation and completed the 
survey for a 23.4% response rate.  The percentage of 
pharmacists who completed the survey by state was 40.9% 
(n=45) in Minnesota, 28.2% (n=31) in Virginia, 11.8% (n=13) in 
Missouri, 13.6% (n=15) in Maryland, 5.5% (n=6) in Illinois, and 
0% in North Carolina.  
 
The majority of pharmacists who already conduct POCT 
perform glucose screenings (71%), followed by hemoglobin A1C 
(26%) and lipid (23%) screenings (Figure 1). A total of 63% of 
pharmacists believe that HIV POCT is within their scope-of-
practice, while 65% believe that HCV POCT is within their scope-
of-practice (Figure 2).  
 
The majority of pharmacists (63%) currently have patients who 
receive antiretroviral therapy. However, the majority of 
pharmacists (83%) do not currently have patients who receive 
medications for the treatment of HCV.  
 
Pharmacists’ opinion of the total amount of time needed to 
conduct a POCT for HIV was found to be 39% for 15 to 30 
minutes and 35% of pharmacists for 30 to 60 minutes (Figure 
3). For HCV POCT, pharmacists’ opinion of the total amount of 
time needed was found to be 41% for 15 to 30 minutes and 34% 
for 30 to 60 minutes (Figure 4).  
 
A specific scenario was posed before a series of questions were 
asked about pharmacists’ level of confidence regarding certain 
situations (see Appendix A). Pharmacists had the highest levels 
of confidence when providing basic education to patients. A 
total of 35% of pharmacists were slightly confident and 32% 
were moderately confident regarding HIV education.  For HCV 
education, 36% of pharmacists were slightly confident and 30% 
were moderately confident. The majority of pharmacists were 
slightly confident (28%) and moderately confident (27%) 
incorporating both HIV and HCV POCT into workflow. 
Pharmacists had the lowest levels of confidence when 
discussing results of a positive preliminary test with patients. A 
total of 22% of pharmacists were not confident or extremely 
unconfident and 17% were extremely unconfident regarding a 
positive HIV test. For a positive HCV test, 25% of pharmacists 
were not confident and 15% were extremely unconfident 
(Figure 5). 
 
Eight perceived barriers were posed and asked if they were 
considered to be a barrier, maybe a barrier, or not a barrier. 
These barriers included: staffing, time to conduct test, out-of-
pocket cost of test to patients, educating patients, training and 
certification, handling false positive results, physical 
assessment to aid in diagnosis, and administrative burden. The 
top three pharmacist-perceived barriers to HIV and HCV POCT 
were staffing, time to conduct test, and patient out-of-pocket 
cost. Less pharmacists perceived educating patients and 
training/certification as barriers (Figure 6).  
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This pilot study provided key information about community 
pharmacists’ readiness for POCT for HIV and HCV. The top three 
pharmacist-perceived barriers to HIV and HCV POCT were 
staffing, time to conduct test, and patient out-of-pocket cost.  
Less pharmacists perceived educating patients and 
training/certification as barriers. Pharmacists had more 
confidence providing basic HIV and HCV education to patients 
as compared to discussing the results of a positive HIV or HCV 
preliminary test.  
 
Several studies have identified diverse barriers to POCT in a 
variety of settings, primarily regarding integration into 
workflow, accuracy of POCT, and pharmacist education and 
training. In one study, barriers to implementation of HIV POCT 
in populations around the world were identified in real-world 
settings between January 1996 to February 2014.14 A total of 
132 studies were identified from a range of study types, 
primarily diagnostic evaluations and surveys, and evaluated by 
two independent reviewers. The authors concluded that the 
majority of barriers found were regarding integration of POCT 
and test device related concerns, such as accuracy. The authors 
discussed that ideal implementation of HIV POCT can be 
achieved with clear protocols, training on quality assurance and 
control, clear communication, and linkage plans to improve 
patient outcomes.  
 
In another study, barriers to implementation of HCV POCT were 
identified in a U.S. community pharmacy study conducted in 
2016.15 A total of 83 patients were tested during a 3-month 
pilot study. Of those tested, 80% denied previous HCV testing 
and 12 of 81 patients self-identified two or more HCV risk 
factors. Only 1.2% of patients were found to be HCV antibody–
positive. Two primary barriers identified by pharmacists 
included recruiting patients for testing and balancing the time 
required to perform, interpret, and provide test results to the 
patient within the normal pharmacy workflow. In general, 
pharmacists were supportive of promoting HCV screening in 
pharmacies both before and after the pilot study. The authors 
concluded that trained and motivated community pharmacists 
have the ability to perform POCT for potentially high-risk 
patients not currently in care. However, this study did not 
identify any facilitators for the implementation of POCT.  
 
On the contrary, the results of another study identified 
different barriers to implementation of HCV POCT in a U.S. 
community pharmacy chain between 2015 to 2016.16 A total of 
1,298 patients aged at least 18 years old with at least one HCV 
risk factor were tested during a 6-month pilot study. Only 8% of 
patients were found to be HCV antibody-positive. One primary 
barrier identified by the authors was lack of follow-up – only 
52% of patients who received a positive result responded 
during the 21- to 28-day follow-up period. Another barrier was 
cost of treatment. The authors concluded their study provided 
evidence in support of point-of-care HCV screening in retail 
pharmacies for at-risk individuals in the U.S. 
 
One study discussed barriers to implementation of infectious 
disease POCT in U.S. community pharmacies between 
November 2012 and May 2013.17 Barriers identified deficits in 
pharmacist education and training, and variance/vagueness in 
state statutes governing the practice of pharmacy. Fewer than 
20% of states address POCT in their statutes and regulations 
governing pharmacy in 2012. The authors concluded that these 
challenges are not insurmountable if pharmacists obtain proper 
training, understand their state regulations and statutes, and 
work with regulators and stakeholders to ensure that such 
services and follow-up care are provided. 
 
Our pilot study confirmed findings from previous studies 
regarding barriers of integration of POCT into workflow and 
pharmacist education and training. Pai et al. found similar 
barriers such as integration into workflow and training. Dong et 
al. also found integration into workflow to be a primary barrier. 
Lastly, Arora et al. also identified handling positive results as a 
barrier.18  
 
Our study did not assess the accuracy of HIV and HCV POCT as 
a barrier. This is because the accuracy of POCTs have been 
demonstrated to be greater than 99%. One barrier that our 
study evaluated that had not been assessed by previous studies 
included the use of physical assessment to aid in diagnosis. In 
addition, this study provided new information about facilitators 
from the scenario-based questions 8 to 12. Participants 
demonstrated that incorporation of POCT into workflow and 
providing basic education for both HIV and HCV were 
facilitators, as they had higher levels of confidence with these 
proposed activities.  
 
There are several limitations of this pilot study. One limitation 
was the potential for response bias due to a low response rate. 
Some plausible reasons for a low response rate include the 
survey being optional and the timing of the survey over two 
major holidays. Another limitation is that pharmacists were not 
provided any background information, such as existing barriers 
about HIV or HCV POCT. This survey assumed that there are 
barriers, pharmacist-perceived or not, to HIV and POCT. In 
addition, not every pharmacist completed all questions of the 
survey. In a few cases, there was a tendency of completing the 
beginning, or more straightforward questions, and not 
answering the remainder of questions before submission. In 
addition, the survey was also conducted by the pharmacists’ 
employer; thus, pharmacists may have felt pressured to answer 
that they were more confident in conducting HIV and HCV 
POCT. Lastly, a more robust analysis including pharmacist 
demographic information could not be completed.  
 
After evaluation of the top three pharmacist-perceived 
barriers, another discussion can be had to overcome these 
barriers. Regarding staffing as a barrier, HIV and HCV POCT 
could be piloted in community pharmacies with more 
pharmacist overlap and during times of the year that don’t 
include holidays and peak flu season. Regarding time to conduct 
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the test as a barrier, pharmacists need education that existing 
HIV and HCV POCTs only take about 15 minutes to conduct, 
similar to other POCTs. In addition, a pilot could initially be 
performed by pharmacists with more clinical responsibilities or 
those who are motivated to provide POCT. These pharmacists 
could set up one-on-one appointments with patients who are 
interested and have never been screened for HIV and HCV. 
Patient out-of-pocket cost is likely the most difficult barrier to 
overcome due to lack of insurance reimbursement of POCT. In 
one study evaluating the implementation of HIV POCT in a 
community pharmacy in 69 participants, most (78.3%) 
indicated they would be willing to pay $16 to $20 or less for the 
HIV test, and only 9% would pay $30 or more.19 Unfortunately, 
cost is likely to remain an issue and barrier for many patient 
populations. 
 
Conclusion 
Understanding barriers perceived by pharmacists will assist 
with potential implementation of HIV and HCV POCT 
throughout a community pharmacy chain. While this study 
found pharmacist support for the implementation of HIV and 
HCV POCT, additional studies are needed before effective 
implementation of HIV and HCV POCT in community pharmacy.  
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Appendix A 
 
Survey Questions 
1. SUPERVALU offers Point-of-Care Testing (POCT) as part of their clinical services. Have you had the opportunity to conduct POCT 
at your pharmacy? If so, which POCT have you conducted? Please select all that apply.  
• Blood glucose 
• A1C 
• Cholesterol 
• Strep 
• Influenza 
• Other (type in response) 
• I have never conducted POCT   
 
2. Do you currently have patients who receive antiretroviral therapy?  
• Yes 
• No 
 
3. Do you currently have patients who receive medications for the treatment of Hepatitis C? 
• Yes 
• No 
 
4. Do you think Point-of-Care Testing (POCT) for HIV is within a pharmacist’s scope-of-practice?  
• Yes 
• No 
 
5. Do you think Point-of-Care Testing (POCT) for Hepatitis C is within a pharmacist’s scope-of-practice?  
• Yes 
• No 
 
6. What would you consider a suitable amount of time to conduct POCT for HIV, including time for potential questions a patient 
may have? 
• 0 to 15 minutes 
• 15 to 30 minutes 
• 30 to 60 minutes  
• More than 60 minutes 
 
7. What would you consider a suitable amount of time to conduct POCT for Hepatitis C, including time for potential questions a 
patient may have? 
• 0 to 15 minutes 
• 15 to 30 minutes 
• 30 to 60 minutes  
• More than 60 minutes 
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For questions 8 through 12, consider the following scenario: SUPERVALU is rolling out a new clinical service – POCT for HIV and 
Hepatitis C. You are a pharmacist working at a store that has been identified to have a high HIV and Hepatitis C population and will 
be required to undergo training and certification to both conduct POCT and provide education to these patients. Each POCT will be 
conducted via an oral swab and will take place during an appointment-based session. In addition, each POCT takes about 15 minutes 
for results.  
 
Please indicate how confident you are... Extremely 
confident 
 
Moderately 
confident 
 
Slightly 
confident 
 
Not 
confident 
Extremely 
unconfident 
8. Incorporating POCT for HIV and Hepatitis C into 
workflow at your store? 
     
9. Providing basic HIV education to a patient?       
10. Providing basic Hepatitis C education to a patient?       
11. Discussing the results of a positive preliminary HIV 
test?  
     
12. Discussing the results of a positive preliminary 
Hepatitis C test?  
     
 
 
For each of the following items related to HIV and Hepatitis C POCT, indicate whether you would consider them to be barriers:  
 
 Yes Maybe No 
13. Staffing    
14. Time to conduct test    
15. Out-of-pocket cost of test to patient     
16. Educating patients     
17. Training and certification     
18. Handling false positive results     
19. Physical assessment to aid in diagnosis    
20. Administrative burden    
 
